Drugs / 2141-V11
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06455605 | Mar 2025 → Jan 2029 expected | IDH-wildtype glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 1 | NCT05126472 | Nov 2021 → Nov 2027 expected | non-invasive bladder urothelial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04547777 | Jul 2021 → Jun 2027 expected | malignant glioma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 1 | NCT04059588 | Jan 2020 → Mar 2023 | skin cancer | Rockefeller University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05734560 | Sep 2023 → Oct 2026 expected | glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06347705 | Mar 2024 → Mar 2029 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2141 V-11 | “Here, we present the results of a phase 1 study on intratumoral administration of an anti-CD40 agonistic antibody (2141-V11) Fc-engineered to enhance FcγRIIB binding.” PMID 38883779 ↗ Jun 20247“2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration.” NCT06455605 ↗ “Drug: 2141 V-11” NCT04059588 ↗ “Drug: 2141 V11” NCT06455605 ↗ |
| Action | Activate | “By activating CD40, cells of the immune system are better able to identify and kill cancer cells.” NCT04059588 ↗ |
| Modality | Monoclonal antibody | “Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11)” NCT04059588 ↗ |
| Route | Other | “2141-V11 will be delivered sequentially directly into the tumor by Convection Enhanced Delivery (CED)” NCT04547777 ↗ |
| Target | CD40 | “The study drug activates a naturally occurring protein called CD40.” NCT04059588 ↗ |